# China National Center for Cardiovascular Diseases: Observational study in Coronary Artery Disease, Coronary Artery Bypass Grafting (2290 participants)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | China National Center for Cardiovascular Diseases |
| Sponsor type | Non-US government |
| Study | TOP-CABG Trial: Follow-up Extension (TOP-CABG FE) |
| NCT ID | NCT07871591 |
| Phase | Observational |
| Status | not yet recruiting |
| Conditions | Coronary Artery Disease; Coronary Artery Bypass Grafting; Dual Antiplatelet Therapy; Bleeding; Myocardial Ischemia; Myocardial Infarction |
| Target enrollment | 2290 |
| Posted | 2026-10-13 |
| Planned start | 2026-10-15 |
| Event | Newly registered study |
| Event date | 2026-10-13 |

## Why this score
- 2290 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07871591). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.